Xenon Pharmaceuticals Stock Surges 40% on Breakthrough Epilepsy Drug Trial Results
Xenon Pharmaceuticals (XENE) shares skyrocketed 40% after its Phase 3 X-TOLE2 study for azetukalner demonstrated unprecedented efficacy in treating focal onset seizures. The 25 mg dose achieved a 53.2% median reduction in monthly seizure frequency, dwarfing the placebo group's 10.4% improvement.
The trial enrolled 380 adults with highly treatment-resistant epilepsy, averaging 12.75 seizures per month despite prior treatments. Remarkably, 54.8% of patients on the 25 mg dose saw seizure frequency halved—a result that exceeded even the optimistic projections from earlier Phase 2b data.
Market reaction was immediate and decisive, with trading volume spiking to five times the 30-day average. The company now plans to file its New Drug Application with the FDA by Q3 2026, potentially positioning azetukalner as a first-line treatment for refractory epilepsy.
